Narrow search
Showing 1 - 10 of 6,031
Cover Image
Comparing Patient Access to Pharmaceuticals in the UK and US
Cohen, Joshua; Cairns, Catherine; Paquette, Cherie; … - In: Applied Health Economics and Health Policy 5 (2006) 3, pp. 177-187
reimbursement and pricing of approved drugs, the so-called fourth and fifth hurdles. Methods: We reviewed 38 National Institute for … approved. Thirdly, we considered whether and when each drug was recommended for reimbursement and use by NICE, and whether … conditions of reimbursement applied. Fourthly, for the subset of FDA-approved drugs, we examined formulary placement, cost …
Persistent link: https://www.econbiz.de/10005590240
Cover Image
New Drugs for Osteoporosis: Comparison of the Costs and Required Returns With Those of Other Drugs Intended for Long-Term Use
Edwards, Martin - In: PharmacoEconomics 15 (1999) 3, pp. 269-278
Specific regulatory guidelines dictate that developing a new drug for osteoporosis will be significantly more expensive and take at least 2 years longer in comparison with other long-term therapies developed using the International Committee on Harmonisation (ICH) general guidelines. Assuming...
Persistent link: https://www.econbiz.de/10005590530
Cover Image
The Selection of Data Sources For Use in Modelling Studies
Nuijten, Mark J.C. - In: PharmacoEconomics 13 (1998) 3, pp. 305-316
Economic analysis has become increasingly important in healthcare in general, and particularly with respect to pharmaceuticals. Therefore, it is vital that the methods used in such evaluations are carefully scrutinised and refined. However, guidelines contain only a limited number of...
Persistent link: https://www.econbiz.de/10005449056
Cover Image
Management of HIV-1 Infection in Children: Special Considerations
Brady, Michael T. - In: Disease Management and Health Outcomes 4 (1998) 2, pp. 73-91
Optimal management of human immunodeficiency virus type 1 (HIV-1)-infected children requires a commitment from the healthcare delivery system, healthcare providers, and affected families and caregivers. When adequate resources are available (as in most industrialised nations), an aggressive...
Persistent link: https://www.econbiz.de/10005448902
Cover Image
Should Antibacterials Be Deregulated?
Rovira, Joan; Figueras, Montserrat; Segu, Josep L. - In: PharmacoEconomics 13 (1998) 5, pp. 499-508
Deregulation of antibacterials is a recurrent topic in the debate on pharmaceutical policy. This article focuses on one aspect of pharmaceutical regulation, namely the requirement of a medical prescription for purchasing antibacterials. However, a strategy of deregulation should not only concern...
Persistent link: https://www.econbiz.de/10005449163
Cover Image
Herbal Remedies: Issues in Licensing and Economic Evaluation
Ashcroft, Darren M.; Li Wan Po, Alain - In: PharmacoEconomics 16 (1999) 4, pp. 321-328
In recent years, the use of alternative therapies has become widespread. In particular, there has been a resurgence in the public's demand for herbal remedies, despite a lack of high-quality evidence to support the use of many of them. Given the increasing pressures to control healthcare...
Persistent link: https://www.econbiz.de/10005405015
Cover Image
A 3-Dimensional View of Access to Licensed and Subsidized Medicines under Single-Payer Systems in the US, the UK, Australia and New Zealand
Ragupathy, Rajan; Aaltonen, Katri; Tordoff, June; … - In: PharmacoEconomics 30 (2012) 11, pp. 1051-1065
licensing bodies and public reimbursement agencies. The present study compares access to licensed and subsidized medicines under …
Persistent link: https://www.econbiz.de/10010579442
Cover Image
Patient Self-Reports in Pharmacoeconomic Studies: Their Use and Impact on Study Validity
Evans, Christopher; Crawford, Bruce - In: PharmacoEconomics 15 (1999) 3, pp. 241-256
The validity of estimates of resource utilisation based on patient recall has not been firmly established. A comprehensive literature search was conducted to identify studies that used patient self-reports to derive estimates of healthcare resource utilisation, direct nonmedical costs and...
Persistent link: https://www.econbiz.de/10005448987
Cover Image
The Cost of Reaching National Cholesterol Education Program (NCEP) Goals in Hypercholesterolaemic Patients: A Comparison of Atorvastatin, Simvastatin, Lovastatin and Fluvastatin
Koren, Michael J.; Smith, Dean G.; Hunninghake, Donald B.; … - In: PharmacoEconomics 14 (1998) 1, pp. 59-70
Objective: Recognising the importance of treating hyperlipidaemia, the National Cholesterol Education Program (NCEP) has established widely accepted treatment goals for low density lipoprotein cholesterol (LDL-C). Medications used most commonly to achieve these LDL-C goals are HMG-CoA reductase...
Persistent link: https://www.econbiz.de/10005449043
Cover Image
The Role of Cost-Consequence Analysis in Healthcare Decision-Making
Mauskopf, Josephine A.; Paul, John E.; Grant, David M.; … - In: PharmacoEconomics 13 (1998) 3, pp. 277-288
A greater understanding of value associated with new pharmaceutical products should lead to better decision-making. Most commonly cost-effectiveness ratios (CERs) are used to indicate value; however, researchers have recently shown that CER estimates are rarely used by decision-makers in making...
Persistent link: https://www.econbiz.de/10005449060